NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,346 | +3.5% | 50,950 | 0.0% | 0.00% | – |
| Q2 2023 | $29,306 | -30.1% | 50,950 | -14.5% | 0.00% | – |
| Q1 2023 | $41,906 | -70.0% | 59,610 | -3.6% | 0.00% | – |
| Q4 2022 | $139,779 | -35.0% | 61,849 | -7.6% | 0.00% | – |
| Q3 2022 | $215,000 | -18.6% | 66,968 | -3.6% | 0.00% | -100.0% |
| Q2 2022 | $264,000 | -79.0% | 69,495 | -70.3% | 0.00% | -50.0% |
| Q1 2022 | $1,260,000 | -59.8% | 233,836 | +0.7% | 0.00% | -60.0% |
| Q4 2021 | $3,137,000 | -29.4% | 232,218 | -6.1% | 0.01% | -37.5% |
| Q3 2021 | $4,443,000 | -4.2% | 247,362 | -8.5% | 0.01% | -11.1% |
| Q2 2021 | $4,638,000 | -13.9% | 270,263 | +0.4% | 0.01% | -18.2% |
| Q1 2021 | $5,386,000 | +15.2% | 269,294 | -2.1% | 0.01% | +10.0% |
| Q4 2020 | $4,676,000 | +49.1% | 275,024 | +45.4% | 0.01% | +25.0% |
| Q3 2020 | $3,137,000 | +54.0% | 189,103 | +114.9% | 0.01% | +60.0% |
| Q2 2020 | $2,037,000 | +29.5% | 87,981 | -0.2% | 0.01% | 0.0% |
| Q1 2020 | $1,573,000 | -16.8% | 88,121 | +0.6% | 0.01% | 0.0% |
| Q4 2019 | $1,891,000 | +18.3% | 87,614 | -0.1% | 0.01% | +25.0% |
| Q3 2019 | $1,598,000 | -48.8% | 87,704 | -0.1% | 0.00% | -55.6% |
| Q2 2019 | $3,124,000 | +6.7% | 87,784 | +0.7% | 0.01% | +12.5% |
| Q1 2019 | $2,929,000 | +2.2% | 87,202 | +0.0% | 0.01% | -11.1% |
| Q4 2018 | $2,865,000 | -46.1% | 87,165 | +0.0% | 0.01% | -40.0% |
| Q3 2018 | $5,314,000 | +24.8% | 87,159 | -0.0% | 0.02% | +15.4% |
| Q2 2018 | $4,257,000 | -54.1% | 87,194 | -0.2% | 0.01% | -53.6% |
| Q1 2018 | $9,282,000 | +78.0% | 87,350 | +0.0% | 0.03% | +75.0% |
| Q4 2017 | $5,216,000 | +132.9% | 87,340 | -6.4% | 0.02% | +128.6% |
| Q3 2017 | $2,240,000 | +22.7% | 93,340 | 0.0% | 0.01% | +16.7% |
| Q2 2017 | $1,825,000 | -16.7% | 93,340 | 0.0% | 0.01% | -25.0% |
| Q1 2017 | $2,191,000 | +91.4% | 93,340 | 0.0% | 0.01% | +100.0% |
| Q4 2016 | $1,145,000 | -29.1% | 93,340 | -0.7% | 0.00% | -33.3% |
| Q3 2016 | $1,615,000 | +21.6% | 94,005 | +0.7% | 0.01% | +20.0% |
| Q2 2016 | $1,328,000 | +3.4% | 93,340 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $1,284,000 | -18.4% | 93,340 | 0.0% | 0.01% | -16.7% |
| Q4 2015 | $1,573,000 | +50.1% | 93,340 | -2.3% | 0.01% | +50.0% |
| Q3 2015 | $1,048,000 | -11.9% | 95,507 | +0.4% | 0.00% | -20.0% |
| Q2 2015 | $1,190,000 | +13.7% | 95,167 | 0.0% | 0.01% | +25.0% |
| Q1 2015 | $1,047,000 | -27.4% | 95,167 | +2.3% | 0.00% | -33.3% |
| Q4 2014 | $1,442,000 | +21.1% | 93,000 | -5.8% | 0.01% | +20.0% |
| Q3 2014 | $1,191,000 | -8.0% | 98,736 | -2.3% | 0.01% | 0.0% |
| Q2 2014 | $1,295,000 | +62.7% | 101,041 | +53.8% | 0.01% | +66.7% |
| Q1 2014 | $796,000 | +12.7% | 65,715 | +5.6% | 0.00% | 0.0% |
| Q4 2013 | $706,000 | +49.3% | 62,237 | +37.5% | 0.00% | +50.0% |
| Q3 2013 | $473,000 | +307.8% | 45,248 | +352.5% | 0.00% | +100.0% |
| Q2 2013 | $116,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |